Clinical Trials

The James Cancer Center Columbus, OH

open for enrollment

Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)

Protocol: OSU-14251

Full Title

A Phase Ib/II Study of Entospletinib (GS-9973) Monotherapy and in Combination with Chemotherapy in Subjects with Acute Myeloid Leukemia (AML)

Purpose

This study will evaluate the efficacy, safety, tolerability, and pharmacodynamics of

entospletinib (GS-9973) when administered as monotherapy or in combination with chemotherapy

in adults with acute myeloid leukemia (AML).

Are you eligible?

Inclusion Criteria:

Adults with AML in need of treatment (except individuals with acute promyelocytic

leukemia M3)

Group A: Individuals > 18 years of age with previously untreated AML who are able to

receive cytarabine amd daunorubicin (7+3) chemotherapy as determined by the treating

physician

Group B: Individuals > 70 years of age with previously untreated AML or individuals <

70 years of age with previously untreated AML who refuse or are unable to receive

cytarabine as determined by the treating physician

Group C: Individuals > 18 years of age with relapsed or refractory AML by WHO

criteria or individuals with previously untreated AML who would have met eligibility

criteria for Groups A or B but refuse or are unable to receive chemotherapy as

determined by the treating physician

Exclusion Criteria:

Known active central nervous system or leptomeningeal lymphoma

Acute Myeloid Leukemia Leukemia